1
Q
Major Depressive Disorder Diagnostic Criteria
A
-depressed mood
-interest deficit
-sleep disturbance
-guilt, worthlessness, regret
Energy loss
-Appetite change
-Psychomotor agitation
-Suicidal ideation
2
Q
First line treatment for Depression
A
- SSRI
- SNRI
- bupropion
- mirtazipine
- vilazodone
- vortioxetine
3
Q
Second line treatment for depression
A
- TCAs
- trazodone
- dextromethorphan
- bupropin
4
Q
Third line for depression
A
MAOIs
5
Q
Transient antidepressant effects
A
- GI effects
- dizziness
- -headache
- sedation/insomnia
- anxiety/jitteriness
6
Q
Chronic adverse effects
A
- sweating
- tremor
- anticholinergic
- BP/HR
- weight change
- sexual side effects
- emotional blunting
- vivid dreams
7
Q
Serious antidepressant effects
A
- Worsening mood
- asthenia
- EPS
- Bruxism
- QT prolongation
- reduced seizure threshold
- bone fracture
- seratonin syndrome
- hyponatremia
8
Q
SSRI ADEs
A
-mild GI effects
-sedation, insominia minimal
-Hyponatremia:check sodium levels within 1 month if over 65
-Caution with HEPATIC inpairment
9
Q
Paroxetine ADE
A
- risk of anticholinergic effects
- most sedating
- greatest risk of weight gain
10
Q
Citalopram and Escitalopram ADE
A
- QT prolongation
11
Q
SNRIs ADE
A
- Constipation
- sedation, insomia
- hyponatremia
- BP/HR elevation
- QT prolongation?
*CAUTION IN RENAL INPAIRMENT
12
Q
Venlafaxine
A
- highest risk for BP/HR elevation
- also used for migraine
- SNRI
13
Q
Duloxetine
Duloxetine
A
- lowest risk for BP/HR elevation
- SNRI also used for neuropathic pain
14
Q
Bupropion(wellbutrin)
A
- NDRI
- most activating antidepressant: insomia, may worsen anxiety
- appetite loss/weight loss
- lower seizure threshold
- low risk of sexual side effects
- renal and hepatic adjustmants
15
Q
Mirtazipine
A
- high risk of sedation and weight gain: less sedation at higher doses
- Anticholinergic
- Low risk of sexual effects
- renal and hepatic dose adjustments
- also used for insomia
16
Q
A
